The KINECT-DCP trial evaluated the efficacy and safety of valbenazine in patients with dyskinesia due to cerebral palsy who experience choreiform movements.

(BPT) – This article was sponsored and developed by Neurocrine Biosciences, Inc. Cerebral palsy (CP) is a neurodevelopmental disorder affecting movement and posture that begins in early childhood ...

Analysts said the outcome is disappointing because there are no approved treatments for dyskinetic cerebral palsy, but the setback had little impact on Neurocrine's valuation.

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Phase 3 KINECT®-DCP study evaluating the efficacy, safety, and tolerability of valbenazine in pediatric and adult participants who ...

Neurocrine Biosciences Phase 3 study of valbenazine for patients with dyskinetic cerebral palsy failed to meet its primary or secondary endpoints. The company said Monday the drug did not meet its ...

Just days after an upbeat R&D event, Neurocrine Biosciences has found itself having to report a phase 3 failure. | Neurocrine’s Ingrezza, approved to treat certain uncontrolled movements, failed to ...

Neurocrine Biosciences has reported that its Phase III trial assessing the selective vesicular monoamine transporter 2 (VMAT2) inhibitor, valbenazine, for dyskinetic cerebral palsy in paediatric and ...

Biosciences announced that its Phase 3 KINECT-DCP study evaluating the efficacy, safety, and tolerability of valbenazine in ...

Neurocrine Biosciences said on Monday its drug failed to meet the main goal in a late-stage clinical trial in patients with a type of disorder that disrupts the brain's ability to control muscles.

A Railway Express truck pulled up at a big yellow brick house on Chicago’s North Drake Avenue one morning last week, and as the deliveryman handed over a package, he said knowingly, “Here’s another ...